Latest news with #HSDT
Business Insider
a day ago
- Business
- Business Insider
Why Is Helius Medical Technologies Stock (HSDT) Up 70% Today?
Helius Medical Technologies (HSDT) stock rocketed higher on Monday after the neurotechnology company announced a positive outcome for its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP). This includes a double-blind randomized clinical trial that met its primary endpoint and confirmed minimal incidence of adverse events and good treatment tolerability. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Helius Medical Technologies noted that these outcomes support its planned submission to the U.S. Food and Drug Administration (FDA). It will submit the PoNS SRP for gait and balance deficit in patients with chronic symptoms of stroke via the Breakthrough Device Designation. HSDT stock was up 70.45% in pre-market trading on Monday, following a 6.08% rally on Friday. However, the stock was still down 98.23% year to date and 98.63% over the past 12 months. With today's rally came heavy trading, as some 10 million shares changed hands, compared to a three-month daily average of about 280,000 units. Is Helius Medical Technologies Stock a Buy, Sell, or Hold? Turning to Wall Street, only one analyst has covered Helius Medical Technologies in the past three months. Maxim Group analyst Anthony Vendetti has a Hold rating and a $2.90 price target for the shares, suggesting a possible 67.42% downside for HSDT stock.
Business Insider
12-06-2025
- Business
- Business Insider
Why Is Helius Medical Tech Stock (HSDT) Up 100% Today?
Helius Medical Technologies (HSDT) stock surged on Wednesday after the neurotech company announced an authorized claim for payment for its Portable Neuromodulation Stimulator (PoNS) from CVS Health (CVS) -owned Aetna Healthcare. This is the third time a major healthcare provider has offered to cover PoNS for a patient. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Dane Andreeff, President and CEO of Helius Medical Tech, said, 'We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis.' PoNS is an orally applied therapy that delivers neurostimulation via a non-implantable mouthpiece. HSDT stock rocketed 98.82% during pre-market trading on Wednesday. That's a welcome change from its 91.50% drop year-to-date and 94.88% fall over the past 12 months. Is Helius Medical Technologies Stock a Buy, Sell, or Hold? Wall Street's coverage of Helius Medical Technologies is thin, but TipRanks' AI analyst Spark fills that gap. Spark rates HSDT stock an Underperform (38) with a $1 price target. The AI analyst cites 'significant financial and operational challenges' as reasons for this rating and price.
Business Insider
24-05-2025
- Business
- Business Insider
Helius Medical files to sell 3.45M shares of common stock
17:14 EDT Helius Medical (HSDT) files to sell 3.45M shares of common stock Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
